Results 21 to 30 of about 2,974 (211)
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker
openaire +2 more sources
Antibiotics, 2022 Therapeutic options for infections caused by vancomycin-resistant enterococci are currently suboptimal. Combination regimens where fosfomycin is used alongside existing treatments are emerging given the proven synergistic potential and PK/PD properties ...
Cristina Lagatolla +4 more
doaj +1 more source
Review of oritavancin for the treatment of acute bacterial skin and skin structure infections [PDF]
Farmacia Hospitalaria, 2018 Objective: To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus ...
Ana Alejandra García Robles +4 more
doaj +1 more source
Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms. [PDF]
, 2020 Staphylococcus aureus biofilms are a significant problem in health care settings, partly due to the presence of a nondividing, antibiotic-tolerant subpopulation. Here we evaluated treatment of S.
Allan, RN +7 more
core +2 more sources
Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota [PDF]
, 2014 Copyright: 2014 Crowther et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Baines, Simon D. +6 more
core +6 more sources
Drugs - Real World Outcomes, 2020 Background Vancomycin treatment of complicated Gram-positive infections is associated with laboratory monitoring, nephrotoxicity, and multiple daily dosing.
Lauren E. Brownell +6 more
doaj +1 more source
Scientific Reports, 2022 Oritavancin is a semisynthetic glycopeptide antibiotic used to treat severe infections by multidrug-resistant Gram-positive pathogens. Oritavancin is known to be a thousand times more potent than vancomycin against Gram-positive bacteria due to the ...
Olatunde P. Olademehin +2 more
doaj +1 more source
Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
Journal of Orthopaedic Surgery and Research, 2019 Background Polymethylmethacrylate (PMMA) is used for local antimicrobial delivery in orthopedic infection. Oritavancin is a long half-life lipoglycopeptide with broad activity against Gram-positive bacteria.
Suzannah M. Schmidt-Malan +4 more
doaj +1 more source
Drugs - Real World Outcomes, 2020 Background Oritavancin is a FDA-approved single-dose IV therapy for the treatment of acute bacterial skin and skin structure infections caused (or suspected to be caused) by certain Gram-positive pathogens, including methicillin-resistant Staphylococcus ...
Sandy Estrada +3 more
doaj +1 more source
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting. [PDF]
, 2016 INTRODUCTION: Introduction of new antibiotics enabling single-dose administration, such as oritavancin may significantly impact site of care decisions for patients with acute bacterial skin and skin structure infections (ABSSSI).
C Marwick +8 more
core +2 more sources